NorthCrest Asset Manangement LLC Makes New $529,000 Investment in Merck & Co., Inc. (NYSE:MRK)

NorthCrest Asset Manangement LLC purchased a new position in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 6,907 shares of the company’s stock, valued at approximately $529,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Financial Avengers Inc. increased its holdings in shares of Merck & Co., Inc. by 115.8% during the 4th quarter. Financial Avengers Inc. now owns 328 shares of the company’s stock valued at $25,000 after purchasing an additional 176 shares in the last quarter. Moisand Fitzgerald Tamayo LLC increased its holdings in shares of Merck & Co., Inc. by 78.0% during the 4th quarter. Moisand Fitzgerald Tamayo LLC now owns 356 shares of the company’s stock valued at $27,000 after purchasing an additional 156 shares in the last quarter. Retirement Group LLC increased its holdings in shares of Merck & Co., Inc. by 116.4% during the 3rd quarter. Retirement Group LLC now owns 608 shares of the company’s stock valued at $30,000 after purchasing an additional 327 shares in the last quarter. Bellwether Advisors LLC increased its holdings in shares of Merck & Co., Inc. by 460.0% during the 3rd quarter. Bellwether Advisors LLC now owns 420 shares of the company’s stock valued at $31,000 after purchasing an additional 345 shares in the last quarter. Finally, Steward Financial Group LLC purchased a new position in shares of Merck & Co., Inc. during the 4th quarter valued at approximately $40,000. 72.88% of the stock is owned by institutional investors.

Shares of NYSE:MRK opened at $88.52 on Thursday. The stock’s 50-day moving average price is $82.29 and its two-hundred day moving average price is $80.30. The company has a current ratio of 1.27, a quick ratio of 1.02 and a debt-to-equity ratio of 0.80. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $91.40. The firm has a market cap of $223.76 billion, a price-to-earnings ratio of 15.84, a PEG ratio of 1.19 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRKGet Rating) last released its quarterly earnings data on Thursday, April 28th. The company reported $2.14 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.31. The business had revenue of $15.90 billion for the quarter, compared to analyst estimates of $14.64 billion. Merck & Co., Inc. had a return on equity of 49.57% and a net margin of 26.27%. The company’s revenue was up 31.6% compared to the same quarter last year. During the same period in the previous year, the company posted $1.40 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 7.31 earnings per share for the current fiscal year.

Several equities research analysts have issued reports on MRK shares. StockNews.com started coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. SVB Leerink lowered their price target on shares of Merck & Co., Inc. from $100.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday, April 21st. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. lowered their price target on shares of Merck & Co., Inc. from $100.00 to $95.00 and set an “overweight” rating on the stock in a research report on Friday, January 28th. Finally, Barclays boosted their price target on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research report on Tuesday, April 12th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Merck & Co., Inc. currently has an average rating of “Buy” and an average target price of $90.69.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Further Reading

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.